

## SEQUENCE LISTING

## 5 (1) GENERAL INFORMATION:

(i) APPLICANTS: Vassilios Papadopoulos  
Martine Culty

10 (ii) TITLE OF INVENTION: Peripheral-type Benzodiazepine Receptor:  
A Tool for Detection, Diagnosis, Prognosis, and Treatment of Cancer

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

15 (A) ADDRESSEE: Pratt & Associates, Inc.  
(B) STREET: 10821 Hillbrooke Lane  
(C) CITY: Potomad  
(D) STATE: MARYLAND  
(E) COUNTRY: USA  
20 (F) ZIP: 20854

(v) COMPUTER READABLE FORM:

25 (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: Apple Macintosh  
(C) OPERATING SYSTEM: Macintosh 7.5  
(D) SOFTWARE: Microsoft Word 6.0

30 (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

35 (vii) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER:  
(B) FILING DATE:

40 (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Sana A. Pratt  
(B) REGISTRATION NUMBER: 39,441  
(C) REFERENCE/DOCKET NUMBER: 009/064/SAP

45 (ix) TELECOMMUNICATION INFORMATION  
(A) TELEPHONE: (301)294-9171  
(B) TELEFAX: (301)294-7357

(2) INFORMATION FOR SEQ ID NO:1:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 652 base pairs  
(B) TYPE: Nucleic acid  
(C) STRANDEDNESS: Single

## (D) TOPOLOGY: Linear

## (ii) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5	CCACGGCGAA	GGTCTCCGCT	GGTACGCCGG	CCTGCAGAAG	40
	CCCTCGTGGC	ACCCGCCCA	CTGGGTGCTG	GGCCCTGTCT	80
	GGGGCACGCT	CTACTCAGCC	ATGGGGTACG	GCTCCTACCT	120
	GGTCTGGAAA	GAGCTGGGAG	GCTTCACAGA	GAAGGCTGTG	160
	GTTCCCCTGG	GCCTCTACAC	TGGGCAGCTG	GCCCTGAACT	200
10	GGGCATGGCC	CCCCATCTTC	TTTGGTGCCTC	GACAAATGGG	240
	CTGGGCCTTG	GTGGATCTCC	TGCTGGTCAG	TGGGGCGGCG	280
	GCAGCCACTA	CCGTGGCCTG	GTACCAGGTG	AGCCCGCTGG	320
	CCGCCCCGCCT	GCTCTACCCC	TACCTGGCCT	GGCTGGCCTT	360
	CACGACCACA	CTCAACTACT	GCGTATGGCG	GGACAACCAT	400
15	GGCTGGCGTG	GGGGACGGCG	GCTGCCAGAG	TGAGTGCCCCG	440
	GCCCACCAGG	GAUTGCAGCT	GCACCAGCAG	GTGCCATCAC	480
	GCTTGTGATG	TGGTGGCCGT	CACGCTTCA	TGACCACTGG	520
	GCCTGCTAGT	CTGTCAGGGC	CTTGGCCCAG	GGGTCAGCAG	560
	AGCTTCAGAG	GTGGCCCCAC	CTGAGCCCCC	ACCCGGGAGC	600
20	AGTGTCTGT	GCTTCTGCA	TGCTTAGAGC	ATGTTCTTGG	640
	AACATGGAAT	TT			652

## (3) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 652 base pairs  
 (B) TYPE: Nucleic acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: Linear

## 30 (ii) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCACGGCGAG	GGTCTCCGCT	GGTACGCCGG	CCTGCAGAAG	40
------------	------------	------------	------------	----

	CCCTCGTGGC	ACCCGCCCA	CTGGGTGCTG	GGCCCTGTCT	80
	GGGGCACGCT	CTACTCAGCC	ATGGGGTACG	GCTCCTACCT	120
	GGTCTGGAAA	GAGCTGGGAG	GCTTCACAGA	GAAGGCTGTG	160
	GTTCCCCTGG	GCCTCTACAC	TGGGCAGCTG	GCCCTGAACT	200
5	GGGCATGGCC	CCCCATCTTC	TTTGGTGCCC	GACAAATGGG	240
	CTGGGCCTTG	GTGGATCTCC	TGCTGGTCAG	TGGGGCGGCG	280
	GCAGCCACTA	CCGTGGCCTG	GTACCAGGTG	AGCCCGCTGG	320
	CCGCCCGCCT	GCTCTACCCC	TACCTGGCCT	GGCTGGCCTT	360
	CACGACCACA	CTCAACTACT	GCGTATGGCG	GGACAACCAT	400
10	GGCTGGCGTG	GGGGACGGCG	GCTGCCAGAG	TGAGTGCCCG	440
	GCCCACCAGG	GACTGCAGCT	GCACCAGCAG	GTGCCATCAC	480
	GCTTGTGATG	TGGTGGCCGT	CACGCTTCA	TGACCACTGG	520
	GCCTGCTAGT	CTGTCAGGGC	CTTGGCCCAG	GGGTCAGCAG	560
	AGCTTCAGAG	GTGGCCCCAC	CTGAGCCCCC	ACCCGGGAGC	600
15	AGTGTCTGT	GCTTTCTGCA	TGCTTAGAGC	ATGTTCTTGG	640
	AACATGGAAT	TT			652

(4) INFORMATION FOR SEQ ID NO:3:

20	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 169 amino acids
	(B) TYPE: amino acid
	(C) TOPOLOGY: Linear
25	(ii) SEQUENCE DESCRIPTION: SEQ ID NO:3:
	Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
	1 5 10
	Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
30	15 20
	Xaa Xaa Xaa Xaa Xaa Xaa His Gly Glu Gly
	25 30
35	Leu Arg Trp Tyr Ala Gly Leu Gln Lys Pro

35 40  
Ser Trp His Pro Pro His Trp Val Leu Gly  
45 50  
5 Pro Val Trp Gly Thr Leu Tyr Ser Ala Met  
55 60  
10 Gly Tyr Gly Ser Tyr Leu Val Trp Lys Glu  
65 70  
Leu Gly Gly Phe Thr Glu Lys Ala Val Val  
75 80  
15 Pro Leu Gly Leu Tyr Thr Gly Gln Leu Ala  
85 90  
Leu Asn Trp Ala Trp Pro Pro Ile Phe Phe  
95 100  
20 Gly Ala Arg Gln Met Gly Trp Ala Leu Val  
105 110  
Asp Leu Leu Leu Val Ser Gly Ala Ala Ala  
115 120  
25 Ala Thr Thr Val Ala Trp Tyr Gln Val Ser  
125 130  
30 Pro Leu Ala Ala Arg Leu Leu Tyr Pro Tyr  
135 140  
Leu Ala Trp Leu Ala Phe Thr Thr Thr Leu  
145 150  
35 Asn Tyr Cys Val Trp Arg Asp Asn His Gly  
155 160  
40 Trp Arg Gly Gly Arg Arg Leu Pro Glu  
165